EUCTR2011-004103-20-GR进行中（未招募）1 期
A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT-464 in Chemotherapy-Naïve Patients with Castration-Refractory Prostate Cancer
Viamet Pharmaceuticals, Inc.0 个研究点目标入组 135 人开始时间: 2011年12月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Patients must have documented histological or cytological evidence of adenocarcinoma of the prostate.
- •2. Patients must have a minimum serum PSA level of >2 ng/ml that is rising based on the Prostate Cancer Working Group 2 criteria.
- •3. Patients must be >18 years of age.
- •4. Patients must have castrate levels of testosterone (<50 ng/ml).
- •5. Patients must have undergone orchiectomy, or have been on LHRH agonists or antagonists, for at least 3 months prior to study entry. Patients on LHRH agonists/antagonists must remain on these agents for the duration of the study.
- •6. Patients must have an ECOG Performance Score of 0 or 1.
- •7. Patients must have adequate hematopoietic function as evidenced by:
- •- WBC >3,000/µl
- •- ANC >1,500/µl
- •- Platelet count >100,000/µl
- •- HGB >10 g/dl
- •8. Patients must have adequate hepatic function as evidenced by AST/ALT levels <3X the ULN and bilirubin levels of <2.0 mg/dl.
- •9. Patients must have adequate renal function as evidenced by a serum creatinine of <2.0 mg/dl
- •10. Patients must have K+ >3.5 mEq/l.
- •11. Patients or their legal representatives must be able to provide written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1. Patients who have received prior cytotoxic chemotherapy for prostate cancer.
- •2. Patients who have received second-line antihormonal therapy, including ketoconazole, aminoglutethimide, or high-dose estrogen within 30 days of study entry.
- •3. Patients who have completed sipuleucel-T treatment within 30 days of study entry
- •4. Patients who have received abiraterone, TAK-700 (Orteronel), TOK-001, or MDV3100, or any other investigational product directed towards the androgen receptor or androgen biosynthesis.
- •5. Patients who have received antiandrogens such as flutamide (EULEXIN®), bicalutamide (CASODEX®), or nilutamide (NILANDRON®) for > 3 months must be off treatment for 6 weeks and demonstrate a continued rise in PSA after withdrawal. Patients on antiandrogens for < 3 months must be off medication for 2 weeks. Patients on 5 alpha reductase inhibitors such as finasteride (PROSCAR®, PROPECIA®), or dutasteride (AVODART®) must stop medication at least 3 months from study entry.
- •6. Patients who require pharmacological or replacement doses of systemic corticosteroids or who have received systemic corticosteroids within 30 days of study entry; use of topical, inhaled or ophthalmic steroids is permitted.
- •7. Patients who have received any investigational agent within 2 weeks of study entry.
- •8. Patients who have received radiotherapy to their primary prostate cancer within 6 weeks of study entry.
- •9. Patients with hepatic or other soft tissue visceral (other than pulmonary) or CNS metastases from prostate cancer.
- •10. Patients with a history of adrenal insufficiency.
- •11. Patients with a history within the last 3 years of another invasive malignancy.
- •12. Patients with a QTcF interval of >470 msec; if the Screening ECG QTc interval is >470 msec, itmay be repeated, and if repeat < 470 msec, the patient may be enrolled.
- •13. Patients who have started on bisphosphonates within 3 months of study entry
- •14. Patients with any intercurrent conditions that could preclude their participation in the study, pose an undue medical hazard, or which could interfere with the interpretation of the study results, including, but not limited to, congestive heart failure (NYHA Class III or IV), unstable angina, cardiac arrhythmia, recent (within the preceding 6 months) myocardial infarction, acute coronary syndrome or stroke, hypertension requiring more than 2 medications for adequate control, or diabetes mellitus with more than 2 episodes of ketoacidosis in the preceding 12 months.
- •15. Patients who have known active HIV, Hepatitis B, or Hepatitis C infections
- •16. Patients with any other medical, psychiatric, or social condition, including substance abuse, which in the opinion of the Investigator would preclude participation in the study.
研究者
相似试验
进行中（未招募）
1 期
A Study of TAK-662 for Japanese Patients with Congenital Protein C DeficiencyJPRN-jRCT2031210209ishizawa Atsushi5
进行中（未招募）
1 期
A Study of TAK-662 for Japanese Patients With Congenital Protein C DeficiencyEUCTR2022-003877-48-Outside-EU/EEATakeda
进行中（未招募）
不适用
A clinical study of a new drug for the treatment of thalassemiaß-thalassemia intermediaMedDRA version: 15.1Level: LLTClassification code 10062923Term: Thalassemia intermediaSystem Organ Class: 100000004850MedDRA version: 15.1Level: LLTClassification code 10054660Term: Thalassemia betaSystem Organ Class: 100000004850EUCTR2012-002499-15-ITACCELERON PHARMA INC
进行中（未招募）
1 期
A Phase 2 study with increasing doses of a new medication called ACE-536 in patients suffering from ß-Thalassemia IntermediaEUCTR2012-002499-15-GRAcceleron Pharma, Inc.50
进行中（未招募）
不适用
A clinical study in patients with Fabry disease to assess the safety, tolerability, and the body processing of the medication PRX-102, which will be given as an infusioMedDRA version: 17.0Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersFabry diseaseEUCTR2012-004786-40-GBProtalix Ltd.18